



TN-1392

Aggregate Analysis of Tirzepatide Using a Biozen™ dSEC-1 SEC Column

Sujatha Chilakala, Ph.D.¹ and Lucia Geis-Asteggianti, Ph.D.²

¹ Phenomenex, Inc., 411 Madrid Ave., Torrance, CA 90501 USA

² Phenomenex, Inc., Via M. Serenari 15/D, Castel Maggiore, BO 40013 ITALY

Introduction


Tirzepatide is a synthetic peptide therapeutic that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors¹. It is used in the management of type 2 diabetes and obesity, functioning by enhancing insulin secretion, suppressing glucagon release, and delaying gastric emptying. These actions contribute to improved glycemic control and significant weight loss². As a large and hydrophobic peptide (molecular weight ~4813 Da), Tirzepatide is prone to aggregation, particularly under stress conditions such as pH shifts, oxidation, and elevated temperatures. Aggregation can compromise product safety, efficacy, and shelf-life, making its detection and quantification a critical aspect of formulation development and quality control.

Size Exclusion Chromatography (SEC) is a key analytical technique employed to monitor aggregation by separating molecular species based on size. However, SEC of peptides and small proteins can be challenging due to their marked susceptibility to non-specific interactions. Hydrophobic and/or ionic interactions may compromise chromatographic performance, leading to issues such as peak tailing or analyte adsorption. Due to Tirzepatide's hydrophobic nature, SEC analysis often requires organic solvents and acidic conditions to ensure accurate resolution.

In this technical note, we demonstrate the successful performance of Biozen dSEC-1 SEC columns for aggregate analysis of Tirzepatide. The hydrophilic nature of the stationary phase imparts inertness to the media which is reflected in the reduced need for organic solvents in the mobile phase, thereby improving chromatographic results and assisting in robust and reproducible method development.

Sample Preparation

Tirzepatide: Mounjaro® 2.5 mg in 0.5 mL contains the following 39 amino acids, glucagon-like peptide-1 analogue drug.



Sample aggregation was further induced by exposure to ambient light for 3 days. All samples were injected before and after light exposure, injecting the commercial solution directly at volumes of 4.00 µL to achieve a load of 20 µg of the Tirzepatide on column. All analyses were done in triplicate.

LC Conditions

Column: A: Biozen 1.6 µm dSEC-1, 90 Å

B: Biozen 3.0 µm dSEC-1, 90 Å

Dimensions: A: 150 x 4.6 mm

B: 300 x 4.6 mm

Part No.: A: [00F-4801-E0](#)

B: [00H-4802-E0](#)

Mobile Phase: (70:30, v/v) 1X PBS*:Acetonitrile

Isocratic: A: 10 minutes

B: 18 minutes

Flow Rate: 0.40 mL/min

Injection: Injection volume selected to introduce 20 µg on

Volume: column

Temperature: Ambient

LC System: Waters ACQUITY® UPLC H-Class

Detection: UV @ 280 nm

*1X PBS (Phosphate Buffered Saline) contains 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.8 mM KH2PO4.

Results and Discussion


In this study, we measured several chromatographic performance features (retention time, peak area, RSD, and resolution peak asymmetry) for both the monomer and aggregate, in a commercial Tirzepatide injection solution using Biozen dSEC-1 SEC columns. Samples tested include the final product as received and the stressed product after 3-day exposure to light. Successful separation between the monomer and aggregate peak was obtained for both column dimensions tested, with the main chromatographic features measured summarized in **Table 1**.

Separation was achieved using a Biozen dSEC-1 SEC column (150 × 4.6 mm, 1.6 µm) in a 10-minute run with resolutions of 1.33 and 1.56, for samples before and after photolytic stress, respectively (**Figure 1**). For both samples, reproducible retention time and peak areas are observed with RSD of ≤0.06 % and ≤4.35 %, respectively. The method exhibits sensitivity well over acceptable values with signal-to-noise ratios of 7.8 and 23, respectively, enabling reliable detection and quantification of the aggregate in both the final product and the stressed sample.

Table 1. Summary of observed retention times, peak areas, % of the species present, resolution between dimer and monomer and peak asymmetry for Tirzepatide before and after photoinduced aggregation (n=3).


Tirzepatide		Biozen dSEC-1 (150 x 4.6 mm, 1.6 μ m)		Biozen dSEC-1 (300 x 4.6 mm, 3 μ m)	
		Aggregate	Monomer	Aggregate	Monomer
Before exposure to light	Retention Time (min)	2.78	2.95	5.69	6.02
	Area (%)	0.17	99.8	0.17	99.8
	Area RSD (%)	3.82	0.15	0.18	0.04
	Resolution	1.33		1.64	
	Peak asymmetry	n.a.	1.57	n.a.	1.78
After exposure to light	Retention Time (min)	2.77	2.95	5.68	6.02
	Area (%)	0.30	99.6	0.22	99.7
	Area RSD (%)	4.35	0.22	3.29	0.05
	Resolution	1.56		1.73	
	Peak asymmetry	n.a.	1.56	n.a.	1.77

Figure 1. Chromatogram of Tirzepatide analyzed with the Biozen dSEC-1 SEC column (150 x 4.6 mm, 1.6 μ m). Traces of a representative injections were made for samples before (blue) and after (red) exposure to light.



When evaluating the Biozen dSEC-1 SEC column (300 x 4.6 mm, 3 μ m) baseline resolved peaks were observed, achieving values of 1.64 and 1.73, for samples before and after photolytic stress, respectively. A representative chromatogram of these samples is shown in **Figure 2**. In this case, good retention time and peak areas reproducibility are observed for both sample types with RSD of ≤ 0.08 % and ≤ 3.29 %, respectively.

Figure 2. Chromatogram of Tirzepatide analyzed with the Biozen dSEC-1 SEC column (300 x 4.6 mm, 3 μ m). Traces of a representative injections were made for samples before (blue) and after (red) exposure to light.



Notably, this excellent performance was achieved using a widely used buffer with a moderate addition of organic solvent (30 % acetonitrile). This outcome further demonstrates that Biozen dSEC-1 SEC column offers a highly hydrophilic stationary phase, making it suitably inert to secondary hydrophobic interactions with therapeutic peptides.

Conclusion

We demonstrated that Biozen dSEC-1 SEC columns are suitable size exclusion columns for Tirzepatide aggregation studies, showing good resolution between aggregate and monomer and excellent retention time and peak area reproducibility. This was achieved without the need of exposing the sample to mobile phases with high organic content or added acidic modifiers.

References

- 1 Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., [...] Drucker, D. J. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. *Molecular Metabolism*, 18, 3–14. <https://doi.org/10.1016/j.molmet.2018.09.009>
- 2 Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. *The New England Journal of Medicine*, 387(3), 205–216. <https://doi.org/10.1056/NEJMoa2206038>



Australia
23-27 Chaplin Drive
Lane Cove NSW 2066, Australia
t: +61 (0)2-9428-6444
f: +61 (0)2-9428-6445
auinfo@phenomenex.com

Austria
Zeppelinstr. 5
63741 Aschaffenburg, Germany
t: +49 (0)6021-58830-0
f: +49 (0)6021-58830-11
anfrage@phenomenex.com

Belgium
Pelmolenlaan 15
3447 GW Woerden
The Netherlands
t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada
411 Madrid Ave.
Torrance, CA
90501-1430, USA
t: +1 (800) 543-3681
f: +1 (310) 328-7768
www.phenomenex.com/support

China
No. 179, Southern Street,
West TEDA, Tianjin, 300462,
China
t: +86 400-606-8099
t: +86 (0)22 2532-1032
f: +86 (0)22 2532-1033
cninfo@phenomenex.com

Czech Republic
c/o Beckman Coulter Česká Republika
s.r.o. V Parku 2316/12,
148 00 Praha 11 – Chodov
t: +420 272 017 077
f: +420 274 021 210
cz-info@phenomenex.com

Denmark
Åkandevej 21
DK-2700 Broenshoej, Denmark
t: +45 4824 8048
nordicinfo@phenomenex.com

Finland
Åkandevej 21
DK-2700 Broenshoej, Denmark
t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France
Parc des Grillons, Bât. 3
60 route de Sartrouville
78232 Le Pecq Cedex, France
t: +33 (0)1 30 09 21 10
f: +33 (0)1 30 09 21 11
franceinfo@phenomenex.com

Germany
Zeppelinstr. 5
63741 Aschaffenburg, Germany
t: +49 (0)6021-58830-0
f: +49 (0)6021-58830-11
anfrage@phenomenex.com

Hong Kong, China
Suite 1605, 16th Floor, Tower 6
China Hong Kong City,
33 Canton Road,
Tsim Sha Tsui, Kowloon,
Hong Kong
f: +852 3102 0003
hkinfo@phenomenex.com

India
Laxmi Cyber City
Ground Floor, B Block
Survey no.: 10
Kondapur, Hyderabad 500 084
India
t: +91 (0)40-3012 2400
f: +91 (0)40-3012 2411
indiainfo@phenomenex.com

Indonesia
PT. DHH Trading Indonesia
Revenue Tower 19th floor, unit #116
Lot.13, District 8 SCBD
Jl. Jendral Sudirman Kav.52-53
Jakarta 12190 Indonesia
t: +62 21 3952 5747
indoinfo@phenomenex.com

Ireland
Phenomenex Ltd
Unit 3
Melville House
Queens Avenue,
Hurdsfield Industrial Estate
Macclesfield
SK10 2BN, UK
t: +353 (0)1 247 5405
f: +44 1625-501796
eireinfo@phenomenex.com

Italy
Via M. Serenari, 15/D
40013 Castel Maggiore (BO)
Italy
t: +39 051 6327511
f: +39 051 6327555
italiainfo@phenomenex.com

Japan
K.K. AB SCIEIX
Gotenyama Trust Tower 21F,
4-7-35 Kita Shinagawa
Shinagawa-ku, Tokyo 140-0001
Japan
t: +81 (0)120-149-262
f: +81 (0)50-3153-1623
jpinfo@phenomenex.com

Luxembourg
Pelmolenlaan 15
3447 GW Woerden
The Netherlands
t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico
411 Madrid Ave.
Torrance, CA
90501-1430, USA
t: 01-800-844-5226
f: 001-310-328-7768
tecnicomx@phenomenex.com

The Netherlands
Pelmolenlaan 15
3447 GW Woerden
The Netherlands
t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand
c/o Beckman Coulter
Unit J, 33-37 Walmsley Road
Otahuhu, 1062 Auckland
New Zealand
t: +64 (0)9-4780951
f: +64 (0)9-4780952
nzinfo@phenomenex.com

Norway
Åkandevej 21
DK-2700 Broenshoej, Denmark
t: +47 810 02 005
nordicinfo@phenomenex.com

Poland
Al. Jerozolimskie 181A
02-222 Warsaw, Poland
t: +48 22 51 02 180
pl-info@phenomenex.com

Portugal
Valgrande 8 Edificio Thanworth II
Planta 2
28108 Alcobendas Madrid,
Spain
t: +351 221-450-488
f: +34 91-413-2290
ptinfo@phenomenex.com

Singapore
1 North Coast Ave, #06-01
Singapore 737663
t: 800-852-3944
sginfo@phenomenex.com

Slovakia
Murmanská 1475/4, 10000 Praha 10,
Czech Republic
t: +420 272 017 077
f: +420 274 021 210
sk-info@phenomenex.com

Spain
Valgrande 8 Edificio Thanworth II
Planta 2
28108 Alcobendas Madrid,
Spain
t: +34 91-413-8613
f: +34 91-413-2290
espinfo@phenomenex.com

Sweden
Åkandevej 21
DK-2700 Broenshoej, Denmark
t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland
Schäferweg 16
4057 Basel, Switzerland
t: +41 (0)61 692 20 20
f: +41 (0)61 692 20 22
swissinfo@phenomenex.com

Thailand
555, Rasa Tower 1, unit 1602-1/1,
16th Floor, Phahonyothin Rd.,
Chatuchak, Chatuchak,
Bangkok, 10900 Thailand
t: +66 (0) 2 566 0287
thaiinfo@phenomenex.com

United Kingdom
Phenomenex Ltd
Unit 3
Melville House
Queens Avenue,
Hurdsfield Industrial Estate
Macclesfield
SK10 2BN, UK
t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA
411 Madrid Ave.
Torrance, CA
90501-1430, USA
t: +1 (310) 212-0555
f: +1 (310) 328-7768
www.phenomenex.com/support

Subject to Phenomenex Standard Terms and Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.
Biozen is a trademark of Phenomenex. ACQUITY is a registered trademark of Waters Corp. Mounjaro is a registered trademark of Eli Lilly and Company.
FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.
© 2025 Phenomenex, Inc. All rights reserved